Recent Advances in Hepatitis C Virus Treatment: Review of HCV Protease Inhibitor Clinical Trials

Chary, Aarthi; Holodniy, Mark
September 2010
Reviews on Recent Clinical Trials;Sep2010, Vol. 5 Issue 3, p158
Academic Journal
Hepatitis C virus (HCV) infection affects millions of people world-wide, and chronic infection can result in end-stage liver disease and hepatocellular carcinoma. Conventional therapy to date has involved combination antiviral therapy including alpha-interferon and ribavirin; response rates with these drugs are variable based on both viral and host factors, such as HCV viral load, HCV genotype, HIV co-infection, host genetic polymorphisms (such as those in the IL28B region), and other factors. Recent advances in HCV treatment have included pegylated forms of alpha-interferon and, more recently, the development of specifically targeted antiviral therapy for HCV (STAT-C) with novel HCV protease inhibitors (PIs) for genotype 1 HCV. Although unlikely to be administered as monotherapy due to the potential for development of HCV PI drug resistance mutations, results of phase II trials of two PIs in development have recently been reported, demonstrating promising therapeutic efficacy of HCV PIs in combination with established conventional treatment. This review outlines the advances and the challenges in the development of these HCV PIs as effective HCV antiviral agents and their role in clinical practice.


Related Articles

  • Antiviral Resistance and the Future Landscape of Hepatitis C Virus Infection Therapy. Wyles, David L. // Journal of Infectious Diseases;Mar2013, Vol. 207 Issue suppl_1, pS33 

    The addition of hepatitis C virus (HCV) protease inhibitors (PIs) to interferon and ribavirin therapy has significantly improved the efficacy of treatment for HCV infection. However, for patients who do not respond to therapy, the selection of HCV variants with resistance to PIs is likely....

  • How INFORM-1 May Change HCV Drug Development. Morrison, Trista // BioWorld Financial Watch;5/4/2009, Vol. 17 Issue 18, p1 

    The article discusses preliminary data on INFORM-1, the first study to combine two direct-acting antivirals for hepatitis C, which was presented at the 44th annual meeting of the European Association for the Study of the Liver (EASL). The encouraging outcomes of the trial are identified, such as...

  • Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease. Wang, Huiqun; Geng, Lingling; Chen, Bo-Zhen; Ji, Mingjuan // Biochemistry & Cell Biology;2014, Vol. 92 Issue 5, p357 

    Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clinical trial recently. However, distinct drug-resistance of Narlaprevir has been discovered. In our study, the molecular mechanisms of drug-resistance of Narlaprevir due to the...

  • Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Scheel, Troels K H; Rice, Charles M // Nature Medicine;Jul2013, Vol. 19 Issue 7, p837 

    More than two decades of intense research has provided a detailed understanding of hepatitis C virus (HCV), which chronically infects 2% of the world's population. This effort has paved the way for the development of antiviral compounds to spare patients from life-threatening liver disease. An...

  • Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Sainz, Bruno; Barretto, Naina; Martin, Danyelle N; Hiraga, Nobuhiko; Imamura, Michio; Hussain, Snawar; Marsh, Katherine A; Yu, Xuemei; Chayama, Kazuaki; Alrefai, Waddah A; Uprichard, Susan L // Nature Medicine;Feb2012, Vol. 18 Issue 2, p281 

    Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. With ?170 million individuals infected and current interferon-based treatment having toxic side effects and marginal efficacy, more effective antivirals are crucially needed. Although HCV protease inhibitors were just...

  • Idenix's valopicitabine on the right track.  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p30 

    The article reports on the results of the phase IIa clinical trial for Indenix Pharmaceuticals Inc.'s hepatitis protease inhibitor valopicitabine. It was shown that the drug has achieved significant viral load reduction after 12 weeks of treatment in patients with chronic hepatitis C virus...

  • Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment-Naive Subjects. Bartels, Doug J.; Yi Zhou; Zhang, Eileen Z.; Marcial, Michelle; Byrn, Randal A.; Pfeiffer, Thomas; Tigges, Ann M.; Adiwijaya, Bambang S.; Chao Lin; Kwong, Ann D.; Kieffer, Tara L. // Journal of Infectious Diseases;9/15/2008, Vol. 198 Issue 6, p800 

    Background. The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their effect on clinical response. Methods....

  • Advances in the Development of Macrocyclic Inhibitors of Hepatitis C Virus NS3-4A Protease. Avoli, Salvatore; Summa, Vincenzo // Current Topics in Medicinal Chemistry;Oct2010, Vol. 10 Issue 14, p1403 

    Hepatitis C virus (HCV) is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and hepatocellular carcinoma (HCC). No vaccine is currently available to prevent hepatitis C, and the current standard of care (SOC) -- pegylated interferon-a (PEG-IFN-a) in combination...

  • Virology: Fresh assault on hepatitis C. Rice, Charles M. // Nature;11/13/2003, Vol. 426 Issue 6963, p129 

    The article focuses on research work related to Hepatitis C virus. As researchers gradually got to grips with viruses that attack the liver, two were identified early on as Hepatitis A and Hepatitis B. But Hepatitis C is a severe medical problem. The virus itself has a tiny genome, consisting of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics